Medication intelligence. Without doubt or disruption .

Sensor-verified dose data. Without changing how patients live or how sites operate.

For clinical trials, pharma medical affairs, and specialty care.

The field measures adherence events.
It does not measure dose.

Pill counts tell you a bottle was opened.

Not the quantity dispensed.

Refill records tell you a prescription was filled.

Not whether it was used.

App check-ins tell you a patient responded.

Not what actually happened.

Topical diaries tell you a tube was used.

Not dose-by-dose dispenses.

What proxies record. What MyAide measures.

Two scenarios. Each panel shows the same week three ways: what actually happened, what a proxy monitor records, and what MyAide measures at the dose level.
Dose verified Underdose Overdose Missed / not recorded
Proxy tech · Pill Cap (MEMS)

Oncology taper failure.

2 tablets daily days 1–5, reducing to 1 tablet daily days 6–7. Patient does not taper.

Actual
Proxy
MyAide
Proxy Monitor

Daily cap-open recorded. Taper failure invisible. Full compliance reported.

MyAide

Correct dosing days 1–5. Overdose flagged days 6–7. Clinician alerted before day 8.

Dose verified Underdose Overdose Missed / not recorded
Proxy tech · Patient App (Self-Report)

Ointment underapplication.

2g daily prescribed. Patient applies ~0.8g most days, overcorrects to 3.2g once. App records all seven as applied.

Actual
Proxy
MyAide
Proxy Monitor

All seven days recorded as applied. No quantity signal.

MyAide

3 days underdose · 1 overdose detected · weekly total 40% below prescribed.

Where the margin between effect and failure is narrow,
that gap is not tolerable.

Oncology

Dosing precision determines whether a therapy works or fails.

CNS

Adherence patterns are invisible until a patient decompensates.

Dermatology

Complex topical regimens collapse silently outside the clinic.

When dose-level precision matters most.

Clinical Trials and Decentralized Trials

Phase 2–4 sponsors and CROs that need adherence data able to withstand regulatory scrutiny. Across oral, topical, and dosage forms.

Pharma Medical Affairs and HEOR

Real-world evidence and outcomes research teams connecting medication behavior to PASI, A1c, or therapy response. With a precision claims data cannot support.

Complex Therapy Management

Transplant, oncology, dermatology, and complex therapy programs where dose-level precision is the difference between a useful signal and a guess.

Our Record to Date.

0 +

Dispense days

Across solid oral and topical dosage forms.

-98%

Dose quantity agreement

Independent validation — topical (Wake Forest University), solid oral (University of Houston).

0 /9

Patents · countries

Two additional patents pending.

0 /5

Patient ease of use

Real-world use across pilot programs.

0 +

Scientific Contributions

Peer-reviewed publications and conference presentations.

Scroll to Top